Obesity (BMI above 40 kg / m2) and overweight (BMI above 27 kg / m2) are the most common risk factors for diabetes. Risk of this endocrine disease increases several times in patients with abdominal obesity with a very large waist circumference.
Phentermine is a drug of choice for treatment of abdominal obesity in patients with diabetes or high risk of this disease. A three-month course of Phentermine helps to get rid of about 5-10% of initial body weight.
This leads to:
Improvement of glycemic control
Increased insulin sensitivity.
Phentermine helps to control appetite, to reduce sugar intake and promote improvement of glycemic control.
Therefore, diabetics using Phentermine may require decrease in a dose of drugs affecting blood sugar level, including such antidiabetic drugs as:
- Glipizide (Glucotrol)
- Glimepiride (Amaryl)
- Insulin (NovoLog, Apidra)
- Chlorpropamide (Diabinese).
To effectively manage weight and restore a balance of glucose in the blood plasma, obese patients with diabetes can be prescribed with combined use of Phentermine and Metformin in low doses.